Emily Bodnar
Stock Analyst at H.C. Wainwright
(3.26)
# 2,446
Out of 5,088 analysts
699
Total ratings
37.4%
Success rate
2.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARTV Artiva Biotherapeutics | Reiterated: Buy | $35 | $4.23 | +727.42% | 12 | Oct 1, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Buy | $45 | $18.61 | +141.81% | 22 | Sep 25, 2026 | |
| AGEN Agenus | Reiterated: Buy | $25 | $7.09 | +252.61% | 42 | Sep 21, 2026 | |
| AUTL Autolus Therapeutics | Reiterated: Buy | $10 | $1.58 | +532.91% | 9 | Sep 21, 2026 | |
| GERN Geron | Reiterated: Hold | n/a | $0.9462 | - | 15 | Sep 21, 2026 | |
| JSPR Jasper Therapeutics | Reiterated: Buy | $20 | $0.532 | +3,659.40% | 23 | Sep 21, 2026 | |
| NKTX Nkarta | Reiterated: Buy | $14 | $1.66 | +743.37% | 32 | Sep 21, 2026 | |
| ODTX Odyssey Therapeutics | Reiterated: Buy | $44 | $19.83 | +121.89% | 3 | Sep 21, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $36 | $7.33 | +391.13% | 48 | Sep 21, 2026 | |
| PPBT Purple Biotech | Reiterated: Buy | $17 | $1.09 | +1,459.63% | 21 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.72 | +157.35% | 28 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $78 | $58.08 | +34.30% | 15 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $26.38 | +59.21% | 12 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $45.23 | +26.04% | 6 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31 | $2.10 | +1,376.19% | 16 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $0.833 | +2,901.20% | 27 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $10.88 | +221.84% | 27 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $1.76 | +979.55% | 25 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $6.53 | +206.51% | 16 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $52 → $60 | $40.42 | +48.44% | 4 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.2017 | +2,378.93% | 39 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.23 | +209.60% | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $55 | $37.23 | +47.73% | 24 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $46 → $52 | $13.11 | +296.64% | 45 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.23 | - | 27 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $0.217 | +5,429.95% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 → $66 | $48.64 | +35.69% | 20 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $4.05 | +344.44% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.0001 | - | 24 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56.01 | $4.65 | n/a | 34 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $1.36 | n/a | 32 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.73 | n/a | 22 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.8354 | n/a | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.731 | n/a | 6 | May 22, 2024 |
Artiva Biotherapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: $35
Current: $4.23
Upside: +727.42%
Arcus Biosciences
Sep 25, 2026
Reiterated: Buy
Price Target: $45
Current: $18.61
Upside: +141.81%
Agenus
Sep 21, 2026
Reiterated: Buy
Price Target: $25
Current: $7.09
Upside: +252.61%
Autolus Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $10
Current: $1.58
Upside: +532.91%
Geron
Sep 21, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.9462
Upside: -
Jasper Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $20
Current: $0.532
Upside: +3,659.40%
Nkarta
Sep 21, 2026
Reiterated: Buy
Price Target: $14
Current: $1.66
Upside: +743.37%
Odyssey Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $44
Current: $19.83
Upside: +121.89%
Olema Pharmaceuticals
Sep 21, 2026
Reiterated: Buy
Price Target: $36
Current: $7.33
Upside: +391.13%
Purple Biotech
Sep 21, 2026
Reiterated: Buy
Price Target: $17
Current: $1.09
Upside: +1,459.63%
Sep 21, 2026
Reiterated: Buy
Price Target: $7
Current: $2.72
Upside: +157.35%
Sep 21, 2026
Reiterated: Buy
Price Target: $78
Current: $58.08
Upside: +34.30%
Sep 21, 2026
Reiterated: Buy
Price Target: $42
Current: $26.38
Upside: +59.21%
Sep 3, 2026
Reiterated: Buy
Price Target: $57
Current: $45.23
Upside: +26.04%
Aug 14, 2026
Reiterated: Buy
Price Target: $31
Current: $2.10
Upside: +1,376.19%
Aug 14, 2026
Reiterated: Buy
Price Target: $25
Current: $0.833
Upside: +2,901.20%
Aug 14, 2026
Reiterated: Buy
Price Target: $35
Current: $10.88
Upside: +221.84%
Aug 13, 2026
Reiterated: Buy
Price Target: $19
Current: $1.76
Upside: +979.55%
Aug 13, 2026
Reiterated: Buy
Price Target: $20
Current: $6.53
Upside: +206.51%
Aug 11, 2026
Rated: Buy
Price Target: $52 → $60
Current: $40.42
Upside: +48.44%
Aug 6, 2026
Reiterated: Buy
Price Target: $5
Current: $0.2017
Upside: +2,378.93%
Aug 6, 2026
Reiterated: Buy
Price Target: $10
Current: $3.23
Upside: +209.60%
Jul 30, 2026
Reiterated: Buy
Price Target: $52 → $55
Current: $37.23
Upside: +47.73%
Jul 24, 2026
Rated: Buy
Price Target: $46 → $52
Current: $13.11
Upside: +296.64%
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $2.23
Upside: -
May 15, 2026
Reiterated: Buy
Price Target: $12
Current: $0.217
Upside: +5,429.95%
Mar 30, 2026
Reiterated: Buy
Price Target: $55 → $66
Current: $48.64
Upside: +35.69%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $4.05
Upside: +344.44%
Nov 17, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.0001
Upside: -
Oct 13, 2025
Reiterated: Buy
Price Target: $56.01
Current: $4.65
Upside: n/a
Sep 26, 2025
Reiterated: Buy
Price Target: $160
Current: $1.36
Upside: n/a
Apr 29, 2025
Rated: Hold
Price Target: n/a
Current: $1.73
Upside: n/a
Mar 31, 2025
Reiterated: Buy
Price Target: $8
Current: $0.8354
Upside: n/a
May 22, 2024
Rated: Hold
Price Target: n/a
Current: $0.731
Upside: n/a